podcast
Biotech layoffs and a big pharma exit
Why are pharmaceutical companies cutting more staff than cash-strapped biotechs? And who will Pfizer scout out as its next science chief? STAT's West Coast biotech reporter Jonathan Wosen joins "The Readout LOUD" to discuss what's driving workforce cuts.
We also discuss a big change in Pfizer's leadership and the debate over a new side effect tied to the diabetes drug Ozempic. Plus, entrepreneurs Alexis Borisy and Zach Weinberg call in to discuss their biotech incubator Curie.Bio and how they hope to "free the founders."
Listen here.
sequencing
Element Biosciences raises another massive round
Element Biosciences, a San Diego-based rival to Illumina, just raised $277 million in Series D venture funding. The funding will help Element commercialize its Ativi benchtop genomic analyzer, and launch its next generation Ativi24 system, which will include cell profiling and multi-omics.
In May, STAT's Jonathan Wosen spoke with Element CEO Molly He, who mentioned that even when the company was raising its previous round in 2021, they weren't ready to go public — and still aren't.
"We wanted to be able to precisely predict what we're going to do in terms of revenue … that takes work and takes an understanding of our customers, of the market, and how our technology has been perceived by the market," she said. "We're getting better and better in our forecast capabilities. But we're still not quite there."
clinical trials
The case for adaptive trial design
Health care is moving toward personalized, patient-focused care, and clinical trials must follow suit with adaptive designs, opine two experts in this space. These trials adjust based on real-time data, speeding up access to new treatments, reducing exposure to ineffective therapies, enhancing patient safety, and improving understanding of drug effects.
Collaboration between tech and patient advocacy can further accelerate medical research and innovation, the experts say. Despite their complexity, advancements in machine learning are making adaptive trials more manageable. Regulatory bodies like the FDA are supporting these designs, recognizing their potential to make drug development more efficient and patient-centric.
Read more.
No comments